齐拉西酮与利培酮治疗儿童少年精神分裂症对照研究

目的探讨齐拉西酮治疗儿童少年精神分裂症的临床疗效和安全性。方法将60例儿童少年精神分裂症患者随机分为两组，每组30例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察8w。于治疗前及治疗2w、4w、6w、8w末采用简明精神病量表评定临床疗效，第8w末采用副反应量表评定不良反应。结果治疗8w末，研究组有效率86．7％，对照组为90％，两组无显著性差异（P〉0.05）；两组治疗第2w末起各时段，简明精神病量表总分均较治疗前显著下降（P〈0.01），同期两组间比较均无显著性差异（P均〉0．05）。两组不良反应多为轻、中度，研究组体质量增加、静坐不能、月经紊乱发生率显著低于对照组（P〈0.01）。结论齐拉西酮治疗儿童少年精神分裂症疗效显著，不良反应轻微，不引起月经紊乱和体质量增加，更适合于儿童少年女性以及身体肥胖患者。

A control study of ziprasidone versus risperidone in child and adolescent schizophrenia

Objective To explore the efficacy and safety of ziprasidone in the treatment of child and adolescent schizophrenia. Methods Sixty child and adolescent schizophrenics were randomly divided into two groups of 30 patinets each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Efficacies were assessed with the Brief Psychiatric Rating Scale（BPRS） before treatment and at the ends of the 2nd, 4th, 6th and 8th week treatment and adverse reactions with the Treatment Emergent Symptom Scale（TESS） at the end of the 8th week. Results At the end of the 8th week, effective rates were respectively 86.7% in the research and 90% in the control group,which showed no significant difference（P〉0.05） ; since the end of the 2nd week, the BPRS total scores of both groups singificantly lowered at each point compared with pretreatment（P〈0.01） and there were no significant differences in contemporary group comparisons（all P〉0.05）. Adverse reactions of both groups were mild to moderate,incidences of increased body weight,akathisia and menstrual disorder were significantly lower in the research than in the control group（P〈0.01）. Conclusion Ziprasidone has an evident effect and mild adverse reactions, does＇nt cause menstrual disorder and increased body weight, and is more suitable for child-adolescent fe male and obesity patients.